OR WAIT null SECS
Kyowa Kirin now leads the commercial efforts for Crysvita in 40 countries, continuing its commitment to address the needs of people living with rare diseases.
Kyowa Kirin, Inc., a leading global specialty pharmaceutical company, has assumed primary commercial leadership for Crysvita (burosumab injection) in the United States and Canada from Ultragenyx Pharmaceutical, Inc., as per their decade-long collaboration plan.
Crysvita, initially discovered and developed by Kyowa Kirin, is used for treating X-linked hypophosphataemia (XLH) in adult and pediatric patients aged 6 months and older and for treating FGF23-related hypophosphataemia in tumor-induced osteomalacia (TIO) associated with tumors that cannot be curatively resected or localized in adult patients. This transition strengthens the company's existing commercial portfolio and underscores its commitment to addressing the needs of people living with rare diseases.
Steve Schaefer, President of Kyowa Kirin North America, commended Ultragenyx's contributions in expediting late-stage trials, securing regulatory approval, and delivering treatment to thousands of patients.
Kyowa Kirin aims to build on the successful launch and broad access established for Crysvita, using learnings from working with XLH and TIO communities worldwide to bring more research, education, and support to North American patients. As part of their collaboration agreement with Ultragenyx, Kyowa Kirin will continue to lead commercial efforts in Latin America and Turkey, while Ultragenyx will provide support for some commercial activities in North America for the next 12 months.